$74.67
0.13% yesterday
NYSE, Sep 24, 10:04 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock price

$74.66
-6.20 7.67% 1M
+3.31 4.64% 6M
+0.63 0.85% YTD
+8.33 12.56% 1Y
-8.93 10.68% 3Y
-0.01 0.01% 5Y
+51.27 219.22% 10Y
+71.01 1,947.33% 20Y
NYSE, Closing price Wed, Sep 24 2025
+0.09 0.12%

Key metrics

Basic
Market capitalization
$43.8b
Enterprise Value
$40.4b
Net debt
positive
Cash
$4.1b
Shares outstanding
587.9m
Valuation (TTM | estimate)
P/E
10.6 | 29.0
P/S
7.7 | 7.1
EV/Sales
7.1 | 6.6
EV/FCF
69.9
P/B
4.2
Financial Health
Equity Ratio
76.6%
Return on Equity
41.8%
ROCE
13.1%
ROIC
15.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$5.7b | $6.2b
EBITDA
$1.7b | $1.8b
EBIT
$1.6b | $1.7b
Net Income
$4.1b | $1.5b
Free Cash Flow
$577.9m
Growth (TTM | estimate)
Revenue
-1.1% | 13.2%
EBITDA
0.2% | 11.8%
EBIT
0.2% | 12.8%
Net Income
181.6% | -63.8%
Free Cash Flow
7.3%
Margin (TTM | estimate)
Gross
78.9%
EBITDA
30.6% | 29.7%
EBIT
27.9%
Net
73.0% | 24.6%
Free Cash Flow
10.2%
More
EPS
$7.1
FCF per Share
$1.0
Short interest
2.0%
Employees
16k
Rev per Employee
$340.0k
Show more

Is Edwards Lifesciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Edwards Lifesciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

43 Analysts have issued a Edwards Lifesciences forecast:

27x Buy
63%
15x Hold
35%
1x Sell
2%

Analyst Opinions

43 Analysts have issued a Edwards Lifesciences forecast:

Buy
63%
Hold
35%
Sell
2%

Financial data from Edwards Lifesciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
5,685 5,685
1% 1%
100%
- Direct Costs 1,201 1,201
7% 7%
21%
4,484 4,484
1% 1%
79%
- Selling and Administrative Expenses 1,881 1,881
4% 4%
33%
- Research and Development Expense 1,055 1,055
1% 1%
19%
1,740 1,740
0% 0%
31%
- Depreciation and Amortization 152 152
0% 0%
3%
EBIT (Operating Income) EBIT 1,588 1,588
0% 0%
28%
Net Profit 4,148 4,148
182% 182%
73%

In millions USD.

Don't miss a Thing! We will send you all news about Edwards Lifesciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edwards Lifesciences Stock News

Neutral
Business Wire
about 12 hours ago
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW). If you currently own shares of Edwards stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. You may also contact Phi...
Neutral
GlobeNewsWire
9 days ago
Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Edwards (EW) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Edwards between February 6, 2024 to July 24, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Positive
MarketBeat
24 days ago
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals and never achieve them.
More Edwards Lifesciences News

Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Head office United States
CEO Bernard Zovighian
Employees 15,800
Founded 1958
Website www.edwards.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today